Taiwan Advance Bio-Pharmaceutical Inc.
Taiwan Advance Bio-Pharmaceutical Inc. operates in the biotechnology industry in China, Germany, USA, Italy, Malaysia, Vietnam, Thailand, Indonesia, Japan, Korea, India, Pakistan, and internationally. The company provides food safety diagnostic testing kits; ELISA, rapid, and chemical test kits customization, and food safety lab establishment consultation services; and manufactures monoclonal and… Read more
Taiwan Advance Bio-Pharmaceutical Inc. (4186) - Total Assets
Latest total assets as of June 2025: NT$692.33 Million TWD
Based on the latest financial reports, Taiwan Advance Bio-Pharmaceutical Inc. (4186) holds total assets worth NT$692.33 Million TWD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Taiwan Advance Bio-Pharmaceutical Inc. - Total Assets Trend (2019–2024)
This chart illustrates how Taiwan Advance Bio-Pharmaceutical Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Taiwan Advance Bio-Pharmaceutical Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Taiwan Advance Bio-Pharmaceutical Inc.'s total assets of NT$692.33 Million consist of 33.8% current assets and 66.2% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 15.7% |
| Accounts Receivable | NT$97.56 Million | 14.4% |
| Inventory | NT$18.70 Million | 2.8% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$195.00K | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Taiwan Advance Bio-Pharmaceutical Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Taiwan Advance Bio-Pharmaceutical Inc.'s current assets represent 33.8% of total assets in 2024, an increase from 33.6% in 2019.
- Cash Position: Cash and equivalents constituted 15.7% of total assets in 2024, down from 16.2% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 4.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 14.4% of total assets.
Taiwan Advance Bio-Pharmaceutical Inc. Competitors by Total Assets
Key competitors of Taiwan Advance Bio-Pharmaceutical Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Taiwan Advance Bio-Pharmaceutical Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Taiwan Advance Bio-Pharmaceutical Inc. generates 0.52x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Taiwan Advance Bio-Pharmaceutical Inc. generates $ 3.38 in net profit.
Taiwan Advance Bio-Pharmaceutical Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.90 | 0.85 | 1.42 |
| Quick Ratio | 0.82 | 0.78 | 1.29 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$-27.29 Million | NT$ -42.44 Million | NT$ 84.25 Million |
Taiwan Advance Bio-Pharmaceutical Inc. - Advanced Valuation Insights
This section examines the relationship between Taiwan Advance Bio-Pharmaceutical Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.65 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | -9.6% |
| Total Assets | NT$676.42 Million |
| Market Capitalization | $19.59 Million USD |
Valuation Analysis
Below Book Valuation: The market values Taiwan Advance Bio-Pharmaceutical Inc.'s assets below their book value (0.03 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Taiwan Advance Bio-Pharmaceutical Inc.'s assets decreased by 9.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Taiwan Advance Bio-Pharmaceutical Inc. (2019–2024)
The table below shows the annual total assets of Taiwan Advance Bio-Pharmaceutical Inc. from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$676.42 Million | -9.64% |
| 2023-12-31 | NT$748.57 Million | +5.91% |
| 2022-12-31 | NT$706.77 Million | -0.98% |
| 2021-12-31 | NT$713.74 Million | -13.32% |
| 2020-12-31 | NT$823.45 Million | +25.70% |
| 2019-12-31 | NT$655.07 Million | -- |